Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study
Nadia Toumeh(Mayo Clinic in Arizona), Aref Al‐Kali(Mayo Clinic), Yazan Khair Eldien Jabban(Rochester Institute of Technology), Cecilia Arana Yi(Mayo Clinic Hospital), Mithun Vinod Shah(Mayo Clinic in Arizona), Dragan Jevremović(Mayo Clinic in Arizona), Rong He(Mayo Clinic), Hemant S. Murthy(University of Florida), James M. Foran(Memorial Sloan Kettering Cancer Center), Aasiya Matin(Mayo Clinic in Arizona), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mehrdad Hefazi(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Kebede H. Begna(Mayo Clinic), William J. Hogan(Mayo Clinic), Antoine N. Saliba(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297